Ultragenyx Pharmaceutical faces securities fraud investigation.

Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. regarding potential securities fraud or unlawful business practices by the company and its officers/directors. The investigation concerns the Phase 3 Orbit study of UX143 for osteogenesis imperfecta. Investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980 to join the class action.

Pomerantz LLP, a leading firm in corporate, securities, and antitrust class litigation, has initiated an investigation into claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). The investigation focuses on whether Ultragenyx and its officers and/or directors have engaged in securities fraud or other unlawful business practices [1].

The investigation was sparked by the announcement on July 9, 2025, that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis. The companies advised that the final analysis would occur around the end of the year [1].

Following this announcement, Ultragenyx's stock price fell significantly, dropping by $10.41 per share, or 25.11%, to close at $31.04 per share on July 10, 2025 [1]. Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980 to join the class action [1].

The Orbit study, conducted in collaboration with Mereo BioPharma Group plc (NASDAO: MREO), is designed to evaluate the safety and efficacy of UX143 in treating OI. The study's progress has been closely monitored by a Data Monitoring Committee, which found UX143 to have an acceptable safety profile and gave the go-ahead for the final analysis [2].

Ultragenyx's CEO, Emil D. Kakkis, expressed eagerness to see the complete results from the Orbit and Cosmic studies later this year. While the study's progress is promising, investors are advised to remain cautious and seek professional advice to understand the potential implications of the ongoing investigation [2].

References:
[1] https://www.marketscreener.com/news/pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-ultragenyx-pharmaceutical-inc-ra-ce7c51dfda8df726
[2] https://finance.yahoo.com/news/mereo-biopharma-group-mreo-announced-134505525.html